QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, B. A Articles by McDevitt, L. M Search for Related Content PubMed PubMed Citation Articles by Brown, B. A Articles by McDevitt, L. M

NEW DRUG DEVELOPMENTS

Fingolimod: A Novel Immunosuppressant for Multiple Sclerosis

Senior Clinical Pharmacist, Partners Multiple Sclerosis Center, Brookline, MA

Pranish P Kantesaria, PharmD

Management Specialty Resident, Department of Pharmacy Services, University of Utah Hospitals and Clinics, Salt Lake City, UT

Lisa M McDevitt, PharmD

Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA

Reprints: Dr. Brown, Partners Multiple Sclerosis Center, 1 Brookline Place West, Ste. 225, Brookline, MA 02445, fax 617/525-6571, bbrown8{at}partners.org

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of fingolimod, a novel immune modulator.

DATA SOURCES: Information was obtained through a MEDLINE search (1966-February 2007) and from published abstracts. Search terms included fingolimod, FTY720, FTY-720, and sphingosine-1-phosphate receptor agonist.

STUDY SELECTION AND DATA EXTRACTION: All English-language studies and abstracts pertaining to fingolimod were considered for inclusion. Preference was given to human data.

DATA SYNTHESIS: Fingolimod is the first in a new class of immune modulators known as the sphingosine-1-phosphate receptor agonists. It is administered orally once daily and causes a dose-related reduction in the number of circulating lymphocytes by preventing their egress from secondary lymph organs, but it does not alter T-cell activation or proliferation. Bradycardia and lymphopenia are the most common adverse effects. Clinical trials have evaluated the efficacy of fingolimod in renal transplantation and multiple sclerosis (MS). Further research for renal transplantation will not take place, but Phase 3 studies in MS are underway, as Phase 2 study results are favorable.

CONCLUSIONS: Due to its distinct mechanism of action and its oral administration, fingolimod may be a useful therapeutic option for patients with relapsing forms of MS. More data are needed to assess the safety and clinical utility of fingolimod.

Key Words: fingolimod, FTY720, immunosuppression, multiple sclerosis, renal transplantation

Published Online, September 4, 2007. www.theannals.com, DOI 10.1345/aph.1G424

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-07-023-H01

This article has been cited by other articles:

				S. M. Camp, R. Bittman, E. T. Chiang, L. Moreno-Vinasco, T. Mirzapoiazova, S. Sammani, X. Lu, C. Sun, M. Harbeck, M. Roe, et al. Synthetic Analogs of FTY720 [2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] Differentially Regulate Pulmonary Vascular Permeability in Vivo and in Vitro J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 54 - 64. [Abstract] [Full Text] [PDF]

				S. Lahiri, H. Park, E. L. Laviad, X. Lu, R. Bittman, and A. H. Futerman Ceramide Synthesis Is Modulated by the Sphingosine Analog FTY720 via a Mixture of Uncompetitive and Noncompetitive Inhibition in an Acyl-CoA Chain Length-de pend ent Manner J. Biol. Chem., June 12, 2009; 284(24): 16090 - 16098. [Abstract] [Full Text] [PDF]